Added to YB: 2024-12-23
Pitch date: 2024-11-09
MSCL.TO [bullish]
Satellos Bioscience Inc.
-3.63%
current return
Author Info
Investing Whisperer shares independent research on micro- and small-caps in Canada and the US. Sign up for the newsletter.
Company Info
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia.
Market Cap
CAD 150.9M
Pitch Price
CAD 10.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.65
P/E
-4.25
EV/Sales
N/A
Sector
Biotechnology
Category
growth
COMPANY ANALYSIS SATELLOS BIOSCIENCE MSCL – TSX / MSCLF-OTC
MSCL.TO: Developing pill to regenerate muscle tissue for DMD. Novel approach targeting stem cells, not gene mutation. Promising dog study results. Ph1 in healthy volunteers, adult DMD patients next. DMD market cap $300M-$5B. Potential for broader muscle regeneration applications. $27M cash, likely needs financing. 15% insider ownership.
Read full article (9 min)